Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease

Behavioural Brain Research

Volumn 296, Issue , 2016, Pages 109-117

  Wang, Shao wei ^a   Yang, Shi gao ^a   Liu, Wen ^a,b   Zhang, Yang xin ^a,b   Xu, Peng xin ^a,c   Wang, Teng ^a,b   Ling, Tie Jun ^b   Liu, Rui Tian ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b ANHUI AGRICULTURAL UNIVERSITY   (China)

^c NINGXIA UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Beta amyloid oligomer; Neuroinflammation; NF B signaling; Oxidative stress; RRR tocopherol quinine

Indexed keywords

ALPHA TOCOPHEROL QUININE; AMYLOID BETA PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ALPHA TOCOPHERYLQUINONE; ANTIOXIDANT; INTERLEUKIN DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; LATENT PERIOD; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPATIAL MEMORY DEFICIT; TRANSGENIC MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; MEMORY DISORDERS; METABOLISM; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKINS; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MICROGLIA; NF-KAPPA B; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SPATIAL MEMORY; VITAMIN E;

EID: 84941711097     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.09.003     Document Type: Article

References (48)

1. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
2. Mattson M.P., Duan W., Wan R., Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 2004, 1:111-116.
3. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
4. Jongbloed W., Bruggink K.A., Kester M.I., Visser P.J., Scheltens P., Blankenstein M.A., et al. Amyloid-beta oligomers relate to cognitive decline in Alzheimer's disease. J. Alzheimers Dis. 2014.
5. Zhou W.W., Lu S., Su Y.J., Xue D., Yu X.L., Wang S.W., et al. Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. Free Radic. Biol. Med. 2014, 74:50-63.
6. Broersen K., Rousseau F., Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimers Res. Ther. 2010, 2:12.
7. Matlack K.E., Tardiff D.F., Narayan P., Hamamichi S., Caldwell K.A., Caldwell G.A., et al. Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:4013-4018.
8. Kim H.G., Moon M., Choi J.G., Park G., Kim A.J., Hur J., et al. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014, 40:23-32.
9. Hefti F., Goure W.F., Jerecic J., Iverson K.S., Walicke P.A., Krafft G.A. The case for soluble Abeta oligomers as a drug target in Alzheimer's disease. Trends Pharmacol. Sci. 2013, 34:261-266.
10. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
11. Capiralla H., Vingtdeux V., Zhao H., Sankowski R., Al-Abed Y., Davies P., et al. Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. J. Neurochem. 2012, 120:461-472.
12. McDonald D.R., Bamberger M.E., Combs C.K., Landreth G.E. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci. 1998, 18:4451-4460.
13. Xu P.X., Wang S.W., Yu X.L., Su Y.J., Wang T., Zhou W.W., et al. Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Abeta oligomer level and attenuating oxidative stress and neuroinflammation. Behav. Brain Res. 2014, 264:173-180.
14. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
15. Boissiere F., Hunot S., Faucheux B., Duyckaerts C., Hauw J.J., Agid Y., et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997, 8:2849-2852.
16. O'Neill L.A., Kaltschmidt C. N.F-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
17. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
18. Mottier P., Gremaud E., Guy P.A., Turesky R.J. Comparison of gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry methods to quantify alpha-tocopherol and alpha-tocopherolquinone levels in human plasma. Anal. Biochem. 2002, 301:128-135.
19. Gille L., Staniek K., Rosenau T., Duvigneau J.C., Kozlov A.V. Tocopheryl quinones and mitochondria. Mol. Nutr. Food Res. 2010, 54:601-615.
20. Crisostomo A.G., Moreno R.B., Navaratnam S., Wilkinson J.A., Bisby R.H. Generation of superoxide and singlet oxygen from alpha-tocopherolquinone and analogues. Free Radic. Res. 2007, 41:730-737.
21. Shrader W.D., Amagata A., Barnes A., Hinman A., Jankowski O., Lee E., et al. Towards a modern definition of vitamin E-evidence for a quinone hypothesis. Bioorg. Med. Chem. Lett. 2012, 22:391-395.
22. Mangialasche F., Xu W., Kivipelto M., Costanzi E., Ercolani S., Pigliautile M., et al. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol. Aging 2012, 33:2282-2290.
23. Yang S.G., Wang W.Y., Ling T.J., Feng Y., Du X.T., Zhang X., et al. Alpha-tocopherol quinone inhibits beta-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines. Neurochem. Int. 2010, 57:914-922.
24. Zhao M., Wang S.W., Wang Y.J., Zhang R., Li Y.N., Su Y.J., et al. Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease. Curr. Alzheimer Res. 2014, 11:69-78.
25. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
26. Niki E. Tocopherylquinone tocopherylhydroquinone. Redox Rep. 2007, 12:204-210.
27. Gille L., Staniek K., Nohl H. Effects of tocopheryl quinone on the heart: model experiments with xanthine oxidase, heart mitochondria, and isolated perfused rat hearts. Free Radic. Biol. Med. 2001, 30:865-876.
28. Palan P.R., Woodall A.L., Anderson P.S., Mikhail M.S. Alpha-tocopherol and alpha-tocopheryl quinone levels in cervical intraepithelial neoplasia and cervical cancer. Am. J. Obstet. Gynecol. 2004, 190:1407-1410.
29. Reed M.N., Hofmeister J.J., Jungbauer L., Welzel A.T., Yu C., Sherman M.A., et al. Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol. Aging 2011, 32:1784-1794.
30. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
31. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
32. Camilleri A., Zarb C., Caruana M., Ostermeier U., Ghio S., Hogen T., et al. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim. Biophys. Acta 2013, 1828:2532-2543.
33. Prangkio P., Yusko E.C., Sept D., Yang J., Mayer M. Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity. PLoS One 2012, 7:e47261.
34. Zhang X., Sun X.X., Xue D., Liu D.G., Hu X.Y., Zhao M., et al. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses. Biochim. Biophys. Acta 2011, 1814:1703-1712.
35. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007, 2:18.
36. Huang H., Xin H., Liu X., Xu Y., Wen D., Zhang Y., et al. Novel anti-diabetic effect of SCM-198 via inhibiting the hepatic NF-kappaB pathway in db/db mice. Biosci. Rep. 2012, 32:185-195.
37. Latta C.H., Brothers H.M., Wilcock D.M. Neuroinflammation in Alzheimer's disease; a source of heterogeneity and target for personalized therapy. Neuroscience 2014.
38. Gonzalez H., Elgueta D., Montoya A., Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J. Neuroimmunol. 2014, 274:1-13.
39. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
40. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
41. Prokop S., Miller K.R., Heppner F.L. Microglia actions in Alzheimer's disease. Acta Neuropathol. 2013, 126:461-477.
42. Verri M., Pastoris O., Dossena M., Aquilani R., Guerriero F., Cuzzoni G., et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int. J. Immunopathol. Pharmacol. 2012, 25:345-353.
43. Tak P.P., Firestein G.S. NF-kappaB a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
44. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 1994, 12:141-179.
45. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
46. Mohmmad Abdul H., Sultana R., Keller J.N., St Clair D.K., Markesbery W.R., Butterfield D.A. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J. Neurochem. 2006, 96:1322-1335.
47. Murakami K., Murata N., Noda Y., Tahara S., Kaneko T., Kinoshita N., et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J. Biol. Chem. 2011, 286:44557-44568.
48. Bayer T.A., Schafer S., Simons A., Kemmling A., Kamer T., Tepest R., et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14187-14192.